FIN.DE TUBIZE ACT.NOUV.
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. It engages in discovering and developing treatments for patients suffering from serious illnesses that affects immune system or central nervous system. The company was incorporated in 1928 and is based in Brussels, Belgium.
Market Cap & Net Worth: FIN.DE TUBIZE ACT.NOUV. (FTD)
FIN.DE TUBIZE ACT.NOUV. (F:FTD) has a market capitalization of $9.66 Billion (€9.41 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #3173 globally and #288 in its home market, demonstrating a -6.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying FIN.DE TUBIZE ACT.NOUV.'s stock price €211.50 by its total outstanding shares 44512598 (44.51 Million).
FIN.DE TUBIZE ACT.NOUV. Market Cap History: 2020 to 2026
FIN.DE TUBIZE ACT.NOUV.'s market capitalization history from 2020 to 2026. Data shows growth from $3.61 Billion to $9.66 Billion (18.64% CAGR).
FIN.DE TUBIZE ACT.NOUV. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how FIN.DE TUBIZE ACT.NOUV.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of FTD by Market Capitalization
Companies near FIN.DE TUBIZE ACT.NOUV. in the global market cap rankings as of March 18, 2026.
Key companies related to FIN.DE TUBIZE ACT.NOUV. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
FIN.DE TUBIZE ACT.NOUV. Historical Marketcap From 2020 to 2026
Between 2020 and today, FIN.DE TUBIZE ACT.NOUV.'s market cap moved from $3.61 Billion to $ 9.66 Billion, with a yearly change of 18.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €9.66 Billion | +1.68% |
| 2025 | €9.50 Billion | +45.25% |
| 2024 | €6.54 Billion | +103.22% |
| 2023 | €3.22 Billion | +2.44% |
| 2022 | €3.14 Billion | -20.55% |
| 2021 | €3.96 Billion | +9.71% |
| 2020 | €3.61 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of FIN.DE TUBIZE ACT.NOUV. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.66 Billion USD |
| MoneyControl | $9.66 Billion USD |
| MarketWatch | $9.66 Billion USD |
| marketcap.company | $9.66 Billion USD |
| Reuters | $9.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.